Hyperkalemia in heart failure: current treatment and new therapeutic perspectives

Minà, Chiara; Ajello, Laura; Gesaro, Gabriele Di; Falletta, Calogero; Clemenza, Francesco

doi:10.31083/j.rcm.2020.02.8

Cited by 5 publications

(3 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the effect of potassium binders on outcomes is unknown. Also, medications such as antibiotics, heparins or nonsteroidal anti-inflammatory drugs can contribute to hyperkalemia [24]. Since our study was retrospective, information on whether the patients received treatment other than HF treatment at that time is limited.…”

Section: Limitationsmentioning

confidence: 99%

Kalp yetmezliği polikliniğinde hiperkaleminin sıklığı ve öngördürücüleri

et al. 2022

View full text Add to dashboard Cite

Objectives: Hyperkalemia is a common and life-threatening condition affecting heart failure (HF) patients. This study aims to show the frequency of hyperkalemia and related factors in the HF outpatient clinic in real world data. Methods: 1146 patients monitored in the HF outpatient clinic with left ventricular ejection fraction ≤ 40% and potassium level ≥ 3.5 mmol/L were included in the study. Results: The median potassium value of the patients was 4.6 [IQR, 4.3-5] mmol/L. It was evaluated in three groups as 3.5-5 mmol/L (normokalaemia), 5.1-5.5 mmol/L (mild hyperkalemia), and ≥ 5.5 mmol/L (moderate to severe hyperkalemia) according to baseline potassium levels. 14.5% of patients had mild hyperkalemia and 7.1% had moderate to severe hyperkalemia. Patients with a potassium value of > 5 mmol/L made up 21.6%. The estimated glomerular filtration rate (eGFR) (OR: 0.968, 95% CI: 0.959-0.977, p

show abstract

Section: Limitationsmentioning

confidence: 99%

Kalp yetmezliği polikliniğinde hiperkaleminin sıklığı ve öngördürücüleri

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Bu etkiler EKG'de sinüs bradikardisi, P dalgalarının kaybolması, dal blokları, 2. veya 3. derece atriyoventriküler blok şeklinde izlenebilir (Tablo 3). [23] Hayatı tehdit…”

Section: Hi̇perkalemi̇ni̇n Kli̇ni̇k Bulgulariunclassified

Management of Hyperkalemia in Heart Failure

Altay

Çavuşoğlu

Çelik

et al. 2021

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society

View full text Add to dashboard Cite

“…Potassium, as a predominant intracellular cation, has been considered to be pivotal in multiple physiological processes related to human health [ 1 ]. Abnormalities in potassium levels could impair the excitability of cells, particularly cardiac myocytes via perturbation of the electric potential across cell membranes [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Potassium levels and the risk of all-cause and cardiovascular mortality among patients with cardiovascular diseases: a meta-analysis of cohort studies

Fan,

Wu,

et al. 2024

Nutr J

View full text Add to dashboard Cite

Background Abnormal blood potassium levels are associated with an increased risk of cardiometabolic diseases and mortality in the general population; however, evidence regarding the association between dyskalemia and mortality among patients with cardiovascular disease (CVD) remains inconclusive. This study aimed to evaluate the association of potassium levels with all-cause and cardiovascular mortality among patients with CVD. Methods PubMed, Embase, Web of Science, and Cochrane Library databases were searched up to August 2023 to identify relevant cohort studies among patients with CVD, such as myocardial infarction, stroke, and heart failure. Abnormal potassium levels were considered as hypokalemia or hyperkalemia. The primary outcomes were all-cause mortality based on follow-up length (including in-hospital, short-term and long-term mortality) and cardiovascular mortality. The methodological quality of included studies was assessed by using the Newcastle-Ottawa Scale. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models. Restricted cubic splines were applied to explore the dose-response relationship. Results Thirty-one cohort studies involving 227,645 participants with an average age of 68.3 years were included in the meta-analysis, all of which achieved moderate to high quality. Hyperkalemia was significantly associated with an approximately 3.0-fold increased risk of all-cause in-hospital mortality (RR:2.78,95CI%:1.92,4.03), 1.8-fold of all-cause short-term mortality (RR:1.80, 95CI%:1.44,2.27), 1.3-fold of all-cause long-term mortality (RR:1.33, 95CI%:1.19,1.48) and 1.2-fold of cardiovascular mortality (RR:1.19, 95CI%:1.04,1.36). Similar positive associations were also observed between hypokalemia and risk of all-cause mortality and cardiovascular mortality. The RRs of all-cause in-hospital, short-term, long-term mortality and cardiovascular mortality with hyperkalemia were attenuated to 2.21 (95CI%:1.60,3.06), 1.46(95CI%:1.25,1.71), 1.23 (95CI%:1.09,1.39) and 1.13 (95CI%:1.00,1.27) when treating hypokalemia together with normokalemia as the reference group. A U-shaped association was observed between potassium levels and mortality, with the lowest risk at around 4.2 mmol/L. Conclusions Both hypokalemia and hyperkalemia were positively associated with the risk of mortality in patients with CVD. Our results support the importance of potassium homeostasis for improving the CVD management. Registration PROSPERO, CRD42022324337.

show abstract

Hyperkalemia in heart failure: current treatment and new therapeutic perspectives

Cited by 5 publications

References 65 publications

Kalp yetmezliği polikliniğinde hiperkaleminin sıklığı ve öngördürücüleri

Kalp yetmezliği polikliniğinde hiperkaleminin sıklığı ve öngördürücüleri

Management of Hyperkalemia in Heart Failure

Potassium levels and the risk of all-cause and cardiovascular mortality among patients with cardiovascular diseases: a meta-analysis of cohort studies

Contact Info

Product

Resources

About